362 related articles for article (PubMed ID: 23624956)
21. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
[TBL] [Abstract][Full Text] [Related]
22. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
23. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
24. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
Fujinaga S; Hirano D; Nishizaki N; Kamei K; Ito S; Ohtomo Y; Shimizu T; Kaneko K
Pediatr Nephrol; 2010 Mar; 25(3):539-44. PubMed ID: 20049616
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
[TBL] [Abstract][Full Text] [Related]
26. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
[TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
30. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
Kolonko A; Piecha G; Więcek A
Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
[TBL] [Abstract][Full Text] [Related]
31. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
[TBL] [Abstract][Full Text] [Related]
32. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.
Tune BM; Mendoza SA
J Am Soc Nephrol; 1997 May; 8(5):824-32. PubMed ID: 9176855
[TBL] [Abstract][Full Text] [Related]
33. Rituximab therapy in nephrotic syndrome: implications for patients' management.
Sinha A; Bagga A
Nat Rev Nephrol; 2013 Mar; 9(3):154-69. PubMed ID: 23338210
[TBL] [Abstract][Full Text] [Related]
34. Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy.
Nara M; Kaga H; Saito M; Abe F; Saito A; Imaizumi C; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2021 Sep; 60(18):2985-2989. PubMed ID: 33776000
[TBL] [Abstract][Full Text] [Related]
35. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
Ren H; Lin L; Shen P; Li X; Xie J; Pan X; Zhang W; Chen N
Oncotarget; 2017 Nov; 8(55):93438-93443. PubMed ID: 29212162
[TBL] [Abstract][Full Text] [Related]
36. Nephrotic syndrome and rituximab: facts and perspectives.
Haffner D; Fischer DC
Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
[TBL] [Abstract][Full Text] [Related]
37. Rituximab treatment for adult patients with focal segmental glomerulosclerosis.
Ochi A; Takei T; Nakayama K; Iwasaki C; Kamei D; Tsuruta Y; Shimizu A; Shiohira S; Moriyama T; Itabashi M; Mochizuki T; Uchida K; Tsuchiya K; Hattori M; Nitta K
Intern Med; 2012; 51(7):759-62. PubMed ID: 22466834
[TBL] [Abstract][Full Text] [Related]
38. Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.
Marasà M; Cravedi P; Ruggiero B; Ruggenenti P
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25155494
[TBL] [Abstract][Full Text] [Related]
39. Minimal change disease and focal segmental glomerulosclerosis in adults: response to steroids and risk of renal failure.
Moura LR; Franco MF; Kirsztajn GM
J Bras Nefrol; 2015; 37(4):475-80. PubMed ID: 26648497
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
